001     119911
005     20240228135000.0
024 7 _ |a 10.1158/1078-0432.CCR-13-2053
|2 doi
024 7 _ |a pmid:24300787
|2 pmid
024 7 _ |a pmc:PMC3962776
|2 pmc
024 7 _ |a 1078-0432
|2 ISSN
024 7 _ |a 1557-3265
|2 ISSN
024 7 _ |a altmetric:1954545
|2 altmetric
037 _ _ |a DKFZ-2017-00502
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Erdreich-Epstein, Anat
|b 0
245 _ _ |a PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas.
260 _ _ |a Philadelphia, Pa. [u.a.]
|c 2014
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1490271717_30686
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a We present here the first report of PID1 (Phosphotyrosine Interaction Domain containing 1; NYGGF4) in cancer. PID1 was identified in 2006 as a gene that modulates insulin signaling and mitochondrial function in adipocytes and muscle cells.Using four independent medulloblastoma datasets, we show that mean PID1 mRNA levels were lower in unfavorable medulloblastomas (groups 3 and 4, and anaplastic histology) compared with favorable medulloblastomas (SHH and WNT groups, and desmoplastic/nodular histology) and with fetal cerebellum. In two large independent glioma datasets, PID1 mRNA was lower in glioblastomas (GBM), the most malignant gliomas, compared with other astrocytomas, oligodendrogliomas and nontumor brains. Neural and proneural GBM subtypes had higher PID1 mRNA compared with classical and mesenchymal GBM. Importantly, overall survival and radiation-free progression-free survival were longer in medulloblastoma patients whose tumors had higher PID1 mRNA (univariate and multivariate analyses). Higher PID1 mRNA also correlated with longer overall survival in patients with glioma and GBM. In cell culture, overexpression of PID1 inhibited colony formation in medulloblastoma, atypical teratoid rhabdoid tumor (ATRT), and GBM cell lines. Increasing PID1 also increased cell death and apoptosis, inhibited proliferation, induced mitochondrial depolaization, and decreased serum-mediated phosphorylation of AKT and ERK in medulloblastoma, ATRT, and/or GBM cell lines, whereas siRNA to PID1 diminished mitochondrial depolarization.These data are the first to link PID1 to cancer and suggest that PID1 may have a tumor inhibitory function in these pediatric and adult brain tumors.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Carrier Proteins
|2 NLM Chemicals
650 _ 7 |a PID1 protein, human
|2 NLM Chemicals
650 _ 7 |a RNA, Messenger
|2 NLM Chemicals
700 1 _ |a Robison, Nathan
|b 1
700 1 _ |a Ren, Xiuhai
|b 2
700 1 _ |a Zhou, Hong
|b 3
700 1 _ |a Xu, Jingying
|b 4
700 1 _ |a Davidson, Tom B
|b 5
700 1 _ |a Schur, Mathew
|b 6
700 1 _ |a Gilles, Floyd H
|b 7
700 1 _ |a Ji, Lingyun
|b 8
700 1 _ |a Malvar, Jemily
|b 9
700 1 _ |a Shackleford, Gregory M
|b 10
700 1 _ |a Margol, Ashley S
|b 11
700 1 _ |a Krieger, Mark D
|b 12
700 1 _ |a Judkins, Alexander R
|b 13
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 14
|u dkfz
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 15
|u dkfz
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 16
|u dkfz
700 1 _ |a Sposto, Richard
|b 17
700 1 _ |a Asgharzadeh, Shahab
|b 18
700 1 _ |a Asgharazadeh, Shahab
|b 19
773 _ _ |a 10.1158/1078-0432.CCR-13-2053
|g Vol. 20, no. 4, p. 827 - 836
|0 PERI:(DE-600)2036787-9
|n 4
|p 827 - 836
|t Clinical cancer research
|v 20
|y 2014
|x 1557-3265
909 C O |o oai:inrepo02.dkfz.de:119911
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2014
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CLIN CANCER RES : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CLIN CANCER RES : 2015
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21